PURPOSE: This study aims to apply longitudinal positron emission tomography (PET) imaging with (18)F-Annexin V to visualize and evaluate cell death induced by doxorubicin in a human head and neck squamous cell cancer UM-SCC-22B tumor xenograft model. PROCEDURES: In vitro toxicity of doxorubicin to UM-SCC-22B cells was determined by a colorimetric assay. Recombinant human Annexin V protein was expressed and purified. The protein was labeled with fluorescein isothiocyanate for fluorescence staining and (18)F for PET imaging. Established UM-SCC-22B tumors in nude mice were treated with two doses of doxorubicin (10 mg/kg each dose) with 1 day interval. Longitudinal (18)F-Annexin V PET was performed at 6 h, 24 h, 3 days, and 7 days after the treatment started. Following PET imaging, direct tissue biodistribution study was performed to confirm the accuracy of PET quantification. RESULTS: Two doses of doxorubicin effectively inhibited the growth of UM-SCC-22B tumors by inducing cell death including apoptosis. The cell death was clearly visualized by (18)F-Annexin V PET. The peak tumor uptake, which was observed at day 3 after treatment started, was significantly higher than that in the untreated tumors (1.56 ± 0.23 vs. 0.89 ± 0.31%ID/g, p < 0.05). Moreover, the tumor uptake could be blocked by co-injection of excess amount of unlabeled Annexin V protein. At day 7 after treatment, the tumor uptake of (18)F-Annexin had returned to baseline level. CONCLUSIONS: (18)F-Annexin V PET imaging is sensitive enough to allow visualization of doxorubicin-induced cell death in UM-SCC-22B xenograft model. The longitudinal imaging with (18)F-Annexin will be helpful to monitor early response to chemotherapeutic anti-cancer drugs.
PURPOSE: This study aims to apply longitudinal positron emission tomography (PET) imaging with (18)F-Annexin V to visualize and evaluate cell death induced by doxorubicin in a human head and neck squamous cell cancer UM-SCC-22B tumor xenograft model. PROCEDURES: In vitro toxicity of doxorubicin to UM-SCC-22B cells was determined by a colorimetric assay. Recombinant humanAnnexin V protein was expressed and purified. The protein was labeled with fluorescein isothiocyanate for fluorescence staining and (18)F for PET imaging. Established UM-SCC-22B tumors in nude mice were treated with two doses of doxorubicin (10 mg/kg each dose) with 1 day interval. Longitudinal (18)F-Annexin V PET was performed at 6 h, 24 h, 3 days, and 7 days after the treatment started. Following PET imaging, direct tissue biodistribution study was performed to confirm the accuracy of PET quantification. RESULTS: Two doses of doxorubicin effectively inhibited the growth of UM-SCC-22B tumors by inducing cell death including apoptosis. The cell death was clearly visualized by (18)F-Annexin V PET. The peak tumor uptake, which was observed at day 3 after treatment started, was significantly higher than that in the untreated tumors (1.56 ± 0.23 vs. 0.89 ± 0.31%ID/g, p < 0.05). Moreover, the tumor uptake could be blocked by co-injection of excess amount of unlabeled Annexin V protein. At day 7 after treatment, the tumor uptake of (18)F-Annexin had returned to baseline level. CONCLUSIONS: (18)F-Annexin V PET imaging is sensitive enough to allow visualization of doxorubicin-induced cell death in UM-SCC-22B xenograft model. The longitudinal imaging with (18)F-Annexin will be helpful to monitor early response to chemotherapeutic anti-cancer drugs.
Authors: P Therasse; S G Arbuck; E A Eisenhauer; J Wanders; R S Kaplan; L Rubinstein; J Verweij; M Van Glabbeke; A T van Oosterom; M C Christian; S G Gwyther Journal: J Natl Cancer Inst Date: 2000-02-02 Impact factor: 13.506
Authors: F G Blankenberg; P D Katsikis; J F Tait; R E Davis; L Naumovski; K Ohtsuki; S Kopiwoda; M J Abrams; H W Strauss Journal: J Nucl Med Date: 1999-01 Impact factor: 10.057
Authors: F G Blankenberg; P D Katsikis; J F Tait; R E Davis; L Naumovski; K Ohtsuki; S Kopiwoda; M J Abrams; M Darkes; R C Robbins; H T Maecker; H W Strauss Journal: Proc Natl Acad Sci U S A Date: 1998-05-26 Impact factor: 11.205
Authors: Fan Zhang; Lei Zhu; Gang Liu; Naoki Hida; Guangming Lu; Henry S Eden; Gang Niu; Xiaoyuan Chen Journal: Theranostics Date: 2011-06-06 Impact factor: 11.556
Authors: Timothy H Witney; Aileen Hoehne; Robert E Reeves; Ohad Ilovich; Mohammad Namavari; Bin Shen; Frederick T Chin; Jianghong Rao; Sanjiv S Gambhir Journal: Clin Cancer Res Date: 2015-05-13 Impact factor: 12.531
Authors: Seth T Gammon; Brian J Engel; Gregory J Gores; Erik Cressman; David Piwnica-Worms; Steven W Millward Journal: Mol Imaging Biol Date: 2020-10 Impact factor: 3.488
Authors: Gang Niu; Lei Zhu; Don N Ho; Fan Zhang; Haokao Gao; Qimeng Quan; Naoki Hida; Takeaki Ozawa; Gang Liu; Xiaoyuan Chen Journal: Theranostics Date: 2013-02-21 Impact factor: 11.556